Red Light Holland Highlights U.S. FDA-Authorized Study Supporting Multi-Session Psilocybin Therapy using Filament Health's Patented PEX010 Botanical Drug Candidate

Study conducted under U.S. FDA Investigational New Drug (IND) authorization by Dr. Anthony Back at the University of Washington Second psilocybin session showed meaningful improvements in anxiety, depression, and overall psychological outcomes, with effects lasting up to 24 weeks 69% of participants fell below clinical thresholds for anxiety and depression after second treatment Research builds on prior studies utilizing Filament's botanical psilocybin drug candidate, PEX010 No serious adverse events reported, even with higher dosing and optional booster administration PEX010 now supplied to 70+ clinical sites globally, supporting trials in depression, PTSD, and cancer-related distress Companies applaud recent U.S. executive action supporting psychedelic research, reinforcing momentum toward regulated, science-driven treatments Toronto, Ontario--(Newsfile Corp. - April 20, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company"), in connection with its proposed acquisition of Filament Health Corp. ("Filament"), is highlighting newly published clinical research that may signal an important shift in the evolution of psychedelic medicine, from single-use interventions toward repeatable, protocol-driven treatment models. A Phase 1 clinical study published in April 2026 in Frontiers in Public Health (link here), conducted under U.S. FDA Investigational New Drug authorization as an investigator-initiated study led by Dr. Anthony Back at the University of Washington evaluated the effects of a second psilocybin-assisted therapy session in patients with metastatic cancer who had only partially responded to an initial treatment.